FREMONT, Calif.--(BUSINESS WIRE)--ARYx Therapeutics Inc. (NASDAQ:ARYX), a biopharmaceutical company, today announced it has completed enrollment in EmbraceAC, a Phase 2/3 double-blind clinical trial comparing its oral anticoagulation therapy, ATI-5923, against the leading anticoagulant agent, warfarin. The purpose of the trial is to evaluate whether ATI-5923 is superior to warfarin in its ability to maintain patients within a target therapeutic range of the level of anticoagulation as measured by INR (International Normalized Ratio). Based upon recent interactions with the U.S. Food and Drug Administration (FDA), ARYx believes this trial could be positioned as one of the required registration studies for ATI-5923.
